Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

DoubleTree Bethesdan

19 sep 2019 7:00 a.m. - 20 sep 2019 3:15 p.m.

8120 Wisconsin Avenue, , Bethesda, MD 20814 , USA

Global Clinical Trial Disclosure and Data Transparency Conference

Learn about the latest global requirements in clinical trial disclosure and data transparency, share best practices, and engage in in-depth discussions on hot topics.

Session 10: US Regulatory and Policy Updates: FDA and ClinicalTrials.gov Developments

Session Chair(s)

Suzanne  Carlson, MA

Suzanne Carlson, MA

Consultant

ABSD Associates, LLC, United States

In 2018, the FDA issued a draft guidance on Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank, meant to address how violations of the requirements of the Final Rule would be identified, under what circumstances civil monetary penalties would be sought, what procedures would apply, and what penalty amounts would be assessed. In 2019, as part of the FDA‘s assessment of the efficiency and transparency of the clinical data used in the regulatory decision-making process for drug and biological products, the agency issued a Federal Register notice to open a docket for public comment on the Clinical Data Summary Report Pilot Program, as well as a new integrated review of marketing applications process and documentation template. Also in 2019, the U.S. Supreme Court reversed and remanded a lower courts’ decision to publicly disclose commercial information that previously had been submitted to the government, thus impacting the government’s stance on transparency and disclosure, an important ruling for FDA-regulated companies who are required to submit commercial information to the Agency. This session will explore these recent developments in the US, and provide a regulatory and policy update from ClinicalTrials.gov.

Speaker(s)

Patrick  McNeilly, PhD

ClinicalTrials.gov Civil Money Penalty Draft Guidance

Patrick McNeilly, PhD

FDA, United States

Senior Health Policy Analyst, Office of Special Medical Programs, OC

Rebecca  Williams, PharmD, MPH

ClinicalTrials.gov Program Updates

Rebecca Williams, PharmD, MPH

Essex, Part of Emmes Group, United States

Senior Clinical Trials Subject Matter Expert

Olivia  Shopshear, MS

FDA Federal Register Notice New Drugs Regulatory Program Modernization: Improving Approval Package Documentation and Communication – PhRMA’s Perspective

Olivia Shopshear, MS

Biogen, United States

Senior Director, US Regulatory Policy Lead

Anne K. Walsh, JD

Secret Keeper: Do Harry Potter and the FDA Have Similar Powers?

Anne K. Walsh, JD

Hyman, Phelps & McNamara, PC, United States

Director

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.